Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Close icon Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.

Osmotica Pharmaceuticals PLC Registered Shs Stock , RVLP

1.32 0.00 0.00%
Official Close 3/17/2023 NAS
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Friday 03/17/2023 the closing price of the Osmotica Pharmaceuticals PLC Registered Shs share was $1.32 on NAS. Compared to the opening price on Friday 03/17/2023 on NAS of $1.27, this is a gain of 3.79%. Osmotica Pharmaceuticals PLC Registered Shs's market capitalization is $116.19 M by 99.26 M shares outstanding.
Is Osmotica Pharmaceuticals stock a Buy, Sell or Hold? Osmotica Pharmaceuticals stock has received a consensus rating of buy. The average rating score is and is based on 4 buy ratings, 1 hold ratings, and 0 sell ratings.
What was the 52-week low for Osmotica Pharmaceuticals stock? The low in the last 52 weeks of Osmotica Pharmaceuticals stock was 0.99. According to the current price, Osmotica Pharmaceuticals is 133.33% away from the 52-week low.
What was the 52-week high for Osmotica Pharmaceuticals stock? The high in the last 52 weeks of Osmotica Pharmaceuticals stock was 2.99. According to the current price, Osmotica Pharmaceuticals is 44.15% away from the 52-week high.
What are analysts forecasts for Osmotica Pharmaceuticals stock? The 5 analysts offering price forecasts for Osmotica Pharmaceuticals have a median target of 4.90, with a high estimate of 8.00 and a low estimate of 2.50. The median estimate represents a 26.94 difference from the last price of 1.32.

Osmotica Pharmaceuticals Stock Snapshot

1.29
Bid
700.00
Bid Size
1.32
Ask
200.00
Ask Size
3/17/2023
Date
8:00 PM
Time
23,300.00
Volume
1.25
Prev. Close
1.27
Open
116.19 M
Market Cap
99.26 M
Number of Shares
1.18
Day Low
1.40
Day High
1.32
0.99
52 Week Low
2.99
52 Week High
1.32
0.00
Dividend
-0.89
P/E Ratio
48.03
Free Float in %

Osmotica Pharmaceuticals Historical Prices

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Osmotica Pharmaceuticals Analyst Data

Total Analysts: 5
Buy Ratings: 4 Neutral Ratings: 1 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 2.50 Median: 4.90 Highest: 8.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Osmotica Pharmaceuticals Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
10/25/22 Barclays Capital
Maintained Buy $3
10/21/22 Jefferies & Company Inc.
Maintained Hold $2.5
12/23/21 H.C. Wainwright & Co.
Maintained Buy $5
09/24/21 Cantor Fitzgerald
Maintained Buy $6
03/17/21 RBC Capital Markets
Maintained Buy $8

Osmotica Pharmaceuticals Estimates* in USD

  2023 2024 2025 2026
Revenue 70 112 177 248
Dividend 0.00 0.00 - -
Dividend Yield (in %) - - - -
EPS - -0.22 0.05 0.42
P/E Ratio -2.83 -6.40 28.57 3.40
EBIT -42 -16 17 60
EBITDA -33 -11 18 53
Net Profit -47 -19 13 59
Net Profit Adjusted -32 -14 -8 31
Pre-Tax Profit -51 -25 8 55
Net Profit (Adjusted) - - - -
EPS (Non-GAAP) ex. SOE -0.46 -0.26 -0.08 0.31
EPS (GAAP) -0.44 -0.22 -0.01 0.29
Gross Income 51 83 134 188
Cash Flow from Investing -9 -9 -9 -9
Cash Flow from Operations -45 -32 1 42
Cash Flow from Financing 130 1 1 -76
Cash Flow per Share - - - -
Free Cash Flow -30 -10 -17 13
Free Cash Flow per Share - - - -
Book Value per Share - - - -
Net Debt - - - -
Research & Development Exp. 4 4 4 4
Capital Expenditure 9 9 9 9
Selling, General & Admin. Exp. 86 91 108 117
Shareholder’s Equity 128 97 104 154
Total Assets 230 202 215 193
  Previous Quarter
ending 12/31/22 		Current Quarter
ending 03/31/23 		Next Quarter
ending 06/30/23 		Current Year
ending 12/31/23 		Next Year
ending 12/31/24
Earnings Estimates
No. of Analysts 4 3 3 6 4
Average Estimate -0.170 USD -0.106 USD -0.100 USD -0.223 USD 0.050 USD
Year Ago -0.240 USD -0.080 USD -0.140 USD - -0.223 USD
Publish Date 3/20/2023 5/11/2023 8/10/2023 - -
Revenue Estimates
No. of Analysts 5 2 2 5 5
Average Estimate 13 USD 14 USD 16 USD 70 USD 112 USD
Year Ago 3 USD 21 USD 8 USD - 70 USD
Publish Date 3/20/2023 5/11/2023 8/10/2023 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Osmotica Pharmaceuticals Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Avista Healthcare Partners, L.P. 01/26/2023 1,032,995.00 n/a n/a Sell No
Venkataraman Sriram 01/26/2023 1,032,995.00 n/a n/a Sell No
Avista Capital Managing Member, LLC 01/26/2023 1,032,995.00 n/a n/a Sell No
Klein Christopher 01/23/2023 9,608.00 186,020.00 1.26 Sell No
Schaub James 01/23/2023 9,608.00 530,412.00 1.26 Sell No
Lask Alisa 08/09/2022 75,000.00 84,557.00 n/a Buy No
Avista Capital Managing Member, LLC 08/07/2022 8,000,000.00 23,730,864.00 1.55 Buy No
MARKISON BRIAN A 08/07/2022 850,000.00 2,976,020.00 1.55 Buy No
Avista Healthcare Partners, L.P. 08/07/2022 8,000,000.00 23,730,864.00 1.55 Buy No
Schaub James 08/07/2022 150,000.00 540,020.00 1.55 Buy No
Venkataraman Sriram 08/07/2022 8,000,000.00 23,730,864.00 1.55 Buy No
Schaub James 05/17/2022 6,273.00 390,020.00 1.40 Sell No
deVries Tina Marie 05/17/2022 5,447.00 136,141.00 1.40 Sell No
Klein Christopher 05/17/2022 6,127.00 195,628.00 1.40 Sell No
Klein Christopher 01/23/2022 9,607.00 201,755.00 1.13 Sell No
Schaub James 01/23/2022 9,607.00 396,293.00 1.13 Sell No
deVries Tina Marie 01/23/2022 9,607.00 141,588.00 1.13 Sell No
Einhorn Andrew J. 01/23/2022 9,607.00 141,473.00 1.13 Sell No
Schaub James 12/15/2021 93,800.00 405,900.00 1.07 Buy No
COWAN GREGORY L 08/26/2021 5,506.00 50,055.00 3.31 Sell No
WEISS FRED G 08/26/2021 5,506.00 118,466.00 3.31 Sell No
WEISS FRED G 07/01/2021 61,188.00 123,972.00 n/a Buy No
WEISS FRED G 06/17/2021 18,584.00 62,784.00 2.89 Sell No
COWAN GREGORY L 06/17/2021 18,584.00 55,561.00 2.89 Sell No
Klein Christopher 05/17/2021 6,467.00 211,362.00 3.12 Sell No

Osmotica Pharmaceuticals Dividend Calendar

Date Name Dividend *yield Currency
2021 Osmotica Pharmaceuticals PLC Registered Shs - - USD
2020 Osmotica Pharmaceuticals PLC Registered Shs - - USD
2019 Osmotica Pharmaceuticals PLC Registered Shs - - USD
2018 Osmotica Pharmaceuticals PLC Registered Shs - - USD
2017 Osmotica Pharmaceuticals PLC Registered Shs - - USD
2016 Osmotica Pharmaceuticals PLC Registered Shs - - USD
*Yield of the Respective Date

Osmotica Pharmaceuticals PLC Registered Shs Calendar

Event Estimate Info Date
Earnings Report -0.170 USD Q4 2022 Earnings Release 03/20/2023
Earnings Report -0.106 USD Q1 2023 Earnings Release 05/11/2023
Earnings Report -0.100 USD Q2 2023 Earnings Release 08/10/2023
Earnings Report - Q3 2023 Earnings Release 11/15/2023
Earnings Report - Q4 2023 Earnings Release 03/27/2024

Osmotica Pharmaceuticals Profile

RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
5
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Osmotica Pharmaceuticals Shareholder

Owner in %
Freefloat 48.03
Avista Capital Holdings LP 23.91
Altchem Ltd. 23.84
Athyrium Capital Management LP 14.71
Athyrium Capital Management LP 14.71
Rovida Advisors, Inc. 3.02
Brian A. Markison, CPA 3.00
AIGH Capital Management LLC 1.82
ArrowMark Colorado Holdings LLC 1.64
Meridian Contrarian Fund 1.64
Alyeska Investment Group LP 1.13
Morgan Stanley Smith Barney LLC 1.10
Renaissance Technologies LLC 0.72
iShares Biotechnology ETF 0.54
James Schaub, MBA 0.53
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.